Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Teva Pharmaceuticals USA Inc.

www.tevausa.com

Latest From Teva Pharmaceuticals USA Inc.

Rozanolixizumab & Biosimilar Ustekinumab Among Raft Of New Drugs Filed In EU

The European Medicines Agency’s latest list of drugs under review for potential marketing approval includes a second generalized myasthenia gravis treatment from UCB and what could become the first biosimilar version of Stelara in the EU.

Europe Drug Review

At The Edge Of The Cliff: Five Blockbuster Drugs Set To Lose US Patent Exclusivity In 2023

With the advent of 2023, comes the start of the industry’s next patent cliff, with five products that reached billions in sales at their peak set to lose US patent exclusivity during the year. Scrip takes a look into how the affected big pharma firms are preparing for anticipated market erosion and which generic and biosimilar companies are positioned to benefit the most.

Scrip Perspectives Generic Drugs

Interchangeable Biosimilars May Qualify For ‘Immediate Substitution’ In Medicare Part D

Proposed policy could help promote uptake of interchangeable biosimilars to AbbVie’s blockbuster Humira. However, some PBMs and insurers are not persuaded that interchangeability is a useful distinction so may not rush to take advantage of the new flexibility.

Biosimilars Medicare

Interchangeable Biosimilars May Qualify For ‘Immediate Substitution’ In Medicare Part D

Proposed policy could help promote uptake of interchangeable biosimilars to AbbVie’s blockbuster Humira. However, some PBMs and insurers are not persuaded that interchangeability is a useful distinction so may not rush to take advantage of the new flexibility.

Biosimilars Medicare
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
UsernamePublicRestriction

Register